Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envafolimab + disitamab vedotin + carboplatin
- Development stage
- Unknown
- Lead developer
- AlphaMab Oncology
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This combination therapy is being investigated as a neoadjuvant treatment regimen, particularly for HER2-mutant non-small-cell lung cancer (NSCLC). It combines an immunotherapy agent (envafolimab), an antibody-drug conjugate (disitamab vedotin), and a platinum-based chemotherapy agent (carboplatin). The combination is currently being studied in a Phase 2 clinical trial called "neovision" (NCT06734182) for resectable HER2-mutant non-small-cell lung cancer. Participants receive a total of 4 cycles during the perioperative period.
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on envafolimab + disitamab vedotin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envafolimab + disitamab vedotin + carboplatin.